Ceryvyn Therapeutics Limited (ASX:CYV)
Australia · Delayed Price · Currency is AUD 0.0110
0.00 (0.00%)
Aug 26, 2026, 4:10 PM AEST
Ceryvyn Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 33.17 | 73.89 | 258.5 | 134.01 | 64.78 | 157.65 |
Cash & Short-Term Investments | 33.17 | 73.89 | 258.5 | 134.01 | 64.78 | 157.65 |
Cash Growth | -84.44% | -71.42% | 92.90% | 106.87% | -58.91% | 155.19% |
Other Receivables | 0.43 | 11.6 | 17.72 | 9.86 | 9.52 | 7.39 |
Receivables | 0.63 | 11.6 | 17.72 | 9.86 | 9.52 | 7.39 |
Prepaid Expenses | 1.74 | 1.14 | 5.84 | 3.96 | 12.66 | 19.19 |
Total Current Assets | 35.54 | 86.64 | 282.06 | 147.83 | 86.95 | 184.22 |
Property, Plant & Equipment | - | - | 0.2 | 0.3 | 0.04 | 0.16 |
Other Long-Term Assets | - | - | 0.7 | 0.08 | 0.16 | 0.23 |
Total Assets | 35.54 | 86.64 | 282.96 | 148.21 | 87.15 | 184.61 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accrued Expenses | - | 1.74 | 1.59 | 1.21 | 0.93 | 0.77 |
Current Portion of Long-Term Debt | - | 376.74 | - | - | - | - |
Current Portion of Leases | - | - | 0.14 | 0.15 | - | 0.15 |
Other Current Liabilities | 1.82 | 14.85 | 94.27 | 26.81 | 16.55 | 3.22 |
Total Current Liabilities | 1.82 | 393.33 | 96.01 | 28.16 | 17.48 | 4.14 |
Long-Term Debt | - | - | 300.56 | 128.7 | - | - |
Long-Term Leases | - | - | - | 0.13 | - | - |
Other Long-Term Liabilities | - | - | 0.01 | 0.01 | 0.04 | 0.02 |
Total Liabilities | 1.82 | 393.33 | 396.58 | 157 | 17.52 | 4.17 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 732.47 | 758.82 | 698.57 | 482.13 | 341.48 | 312.31 |
Retained Earnings | -752.15 | -1,133 | -868.86 | -540.09 | -314.87 | -165.56 |
Comprehensive Income & Other | 53.4 | 67.02 | 56.67 | 49.17 | 43.02 | 33.69 |
Total Common Equity | 33.72 | -306.69 | -113.62 | -8.79 | 69.63 | 180.44 |
Shareholders' Equity | 33.72 | -306.69 | -113.62 | -8.79 | 69.63 | 180.44 |
Total Liabilities & Equity | 35.54 | 86.64 | 282.96 | 148.21 | 87.15 | 184.61 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | - | 376.74 | 300.7 | 128.98 | - | 0.15 |
Net Cash (Debt) | 33.17 | -302.85 | -42.2 | 5.03 | 64.78 | 157.5 |
Net Cash Growth | - | - | - | -92.24% | -58.87% | 156.04% |
Net Cash Per Share | 0.03 | -0.25 | -0.07 | 0.01 | 0.18 | 0.49 |
Filing Date Shares Outstanding | 1,368 | 1,231 | 1,231 | 467.16 | 352.15 | 351 |
Total Common Shares Outstanding | 1,368 | 1,231 | 1,091 | 467.16 | 352.15 | 351 |
Working Capital | 33.72 | -306.69 | 186.06 | 119.66 | 69.47 | 180.08 |
Book Value Per Share | 0.02 | -0.25 | -0.10 | -0.02 | 0.20 | 0.51 |
Tangible Book Value | 33.72 | -306.69 | -113.62 | -8.79 | 69.63 | 180.44 |
Tangible Book Value Per Share | 0.02 | -0.25 | -0.10 | -0.02 | 0.20 | 0.51 |